Large-cap Health Care company Moderna has logged a -0.7% change today on a trading volume of 7,665,965. The average volume for the stock is 11,820,253.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. Based in Cambridge, United States the company has 5,800 full time employees and a market cap of $13,439,014,912.
The company is now trading -36.86% away from its average analyst target price of $55.05 per share. The 22 analysts following the stock have set target prices ranging from $25.0 to $212.0, and on average give Moderna a rating of hold.
Over the last 12 months MRNA shares have declined by -66.2%, which represents a difference of -74.9% when compared to the S&P 500. The stock's 52 week high is $170.47 per share and its 52 week low is $29.25. Based on Moderna's average net margin growth of 21.1% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 6,848,000 | -4,714,000 | -69 | -260.47 |
| 2022 | 19,263,000 | 8,362,000 | 43 | -34.85 |
| 2021 | 18,471,000 | 12,202,000 | 66 | 170.97 |
| 2020 | 803,000 | -747,000 | -93 | 89.15 |
| 2019 | 60,000 | -514,000 | -857 | -200.7 |
| 2018 | 135,068 | -384,734 | -285 |
